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In this study, using mesoporous silica for the solubility enhancement of poorly water-
soluble drug was investigated. Although the incorporating drug into mesoporous silica is
generally performed through the solvent method, the new melting method was proposed
in the present study. Fenofibrate, a poorly water-soluble drug, was incorporated into
mesoporous silica by solvent method and melting method. The obtained samples were
observed by SEM and their physicochemical properties were evaluated by PXRD and DSC
measurement. The dissolution and supersaturated property were also investigated.
The results from SEM, PXRD and DSC measurement showed that drug could be loaded
into pore via the melting method as well as by the solvent method. The drug loaded
quantity depended on the pore volume. Drug up to 33% could be incorporated into mes-
oporous silica and existed in amorphous state. When drug was overloaded or difficulty in
incorporation into pore was found, recrystallization of drug occurred at the outer surface of
mesoporous silica. From the dissolution test, samples prepared by solvent method and
melting method gave the supersaturated drug concentration which sample from melting
method showed superior dissolution to the one from solvent method. From this study,
drug was efficiently incorporated into mesoporous silica by the melting method which is a
simple and solvent-free process, and the aqueous solubility enhancement of poorly water-
soluble drug was achieved.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.bs., Astellas Pharma Inc.,
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Using mesoporous silica has recently gained attention as one
of alternative methods to improve the drug solubility. Meso-
porous silica is a surfactant template with synthesized meso
pore sizes approximately 2e50nm.Due to its unique structural
characteristics, i.e. uniform pore diameter and vast surface
area [1,2], mesoporous silica has been applied to various fields
such as separation, catalysis, and synthesis [3e5]. Size and
molecular arrangement of drug in the pore of mesoporous
silica can be controlled simultaneously with the drug
amorphization and size reduction to nano level [6e9]. Thiswill
lead to the significant difference in dissolution property
compared to the formulation containing bulk crystalline drug.
However, to date the method used to incorporate drug into
mesoporous silica is the solventmethodwhere solvent is used
and the drying step is required to remove solvent in the final
step. This results in the more complicated inclusion process
and problems when applied to pharmaceutical production.
The purpose of this study was to establish the simple and
effectivemethod for incorporating drug intomesoporous silica.
In addition to a conventional solvent method, drug in molten
state was included in mesoporous silica by melting method.
Fenofibrate was used as a model of poorly water-soluble drug.
Severalmethodshavebeenstudied toenhance itspooraqueous
solubility such as micronization and solid dispersion [10,11].
Fenofibrate loading into mesoporous silica by solvent method
and melting method were investigated at various ratios. More-
over, inclusion drug into themacromolecule used as precursor
formesoporous silicawasperformed.Molecular state of drug in
thepreparedsampleswasevaluatedusingdifferential scanning
calorimetry and powder X-ray diffractometry. Dissolution of
fenofibrate loaded in the mesoporous silica by different
methods and their supersaturated condition were studied.2. Materials and methods
2.1. Materials
Fenofibrate was purchased from SigmaeAldrich. Its chemical
structure is shown in Fig. 1. Mesoporous silica samples were
prepared by using Pluronic 123 [(EO)20(PO)70(EO)20 triblock
copolymer] and sodium silicate solution purchased from Sig-
maeAldrich. All other chemicals and solvents were of reagent
or HPLC grade and purchased from Kanto Chemicals (Japan).
2.2. Methods
2.2.1. Preparation of mesoporous silica
Mesoporous silica was synthesized by the previous reported
method [7e12] using Pluronic 123 as a template. An amount ofO
OCl
OO
Fig. 1 e Chemical structure of fenofibrate.4.00 g of Pluronic 123 was added to 120 g of 2.00 N HCl solution
and stirred until fully dissolved. Sodium silicate solution
(10.2 g) was diluted with 30 g of deionized water. The latter
solution was poured into the Pluronic 123 solution while
stirring at 35 C. Then, the solution was kept under static
condition at 35 C for 24 h. The mixture was transferred to a
Teflon-lined autoclave and aged at 90 C for 48 h. The mixture
was cooled to room temperature and filtered through a
0.45 mm membrane filter. Subsequently, obtained white pow-
der was washed with deionized water and dried at 45 C for
60 h. The silicaePluronic 123 composite sample was referred
to as “Pre MPS”. The Pre MPS solid was calcined at 550 C for
8 h to remove the Pluronic 123 template. This synthesized
mesoporous silica was called “MPS”.
2.2.2. Drug loading by solvent method
MPS or Pre MPS sample was soaked into 50 mg/ml of fenofi-
brate in dichloromethane. Themoist powderwas stirred using
a spatula for pre-drying. Then, dichloromethane was
completely evaporated in a water bath at 50 C. The samples
obtained by the solventmethodwere named as “Solv-MPS (FF:
X%)” or “Solv-Pre MPS (FF: X%)”. X% represented the weight
percent of loaded fenofibrate (FF) in fenofibrateeMPS or
fenofibrateePre MPS composite.
2.2.3. Drug loading by melting method
MPS or PreMPS samplewasmixedwith fenofibrate in amortar
to obtain a physical mixture, PM. PM was transferred to a
stainless steel container and heated at 100 C for 1 h to melt
fenofibrate. The samples obtained by the melting method
were named as “Melt-MPS (FF:X%)” or “Melt-PreMPS (FF:X%)”.
X% represented the weight percent of loaded fenofibrate (FF)
in fenofibrateeMPS or fenofibrateePre MPS composite.
2.2.4. Scanning electron microscopy (SEM)
Themorphology of prepared sampleswas observed using field
emission scanning electronmicroscopy (JSM-6700F, JEOL Inc.).
The samples were fixed on aluminum stabs using double-
sided adhesive tape and coated with Au through a sputter-
coater. SEM micrographs were obtained at an accelerated
voltage of 3 kV.
2.2.5. Powder X-ray diffractometry (PXRD)
Crystallinity of the sample was analyzed using powder X-ray
diffractometer (RINT-TTRIII, Rigaku) with Cu Ka radiation
source. The sample was applied on a glass plate. The mea-
surement was performed at a voltage of 50 kV and a current of
300mA. The observed range was from 3 to 40 (2q) with a step
size of 0.02.
2.2.6. Differential scanning calorimetry (DSC)
Thermal analysis was performed using differential scanning
calorimetry (DSC Q1000, TA instrument). Approximately 2 mg
of sample was weighed in a crimped aluminum pan and
measured under nitrogen purge with a heating rate of 10 C/
min over the temperature range of 50 Ce200 C.
2.2.7. Dissolution test
Dissolution test was carried out by using a USP apparatus II
(DT-810, JASCO) with a paddle speed of 75 rpm at 37 C. A
Fig. 2 e SEM micrographs of Pre MPS and MPS; (A) Pre MPS, (B) and (C) MPS.
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used as dissolution medium to evaluate a dissolution profile
under a supersaturated condition. The sample corresponding
to 20.0 mg of fenofibrate was added into the vessel. Sampling
time was at 5, 10, 15, 30, 45, 60 and 120 min. At each sampling,
10 ml of sample solution was drawn and filtered through a
0.45 mm membrane filter. Then, 1.0 ml of the filtrate was
diluted with 0.50 ml of acetonitrile and analyzed by HPLC.
2.2.8. HPLC analysis
The amount of dissolved fenofibrate in dissolution medium
was determined by HPLC analysis (Agilent 1100, Agilent). A
modified USP method was used. The mobile phase consisted
ofmethanol and phosphate buffer (pH 2.9) in a volume ratio of
4/1 and the flow ratewasmaintained at 1.0ml/min. For a HPLC
column, a C18 column (X Bridge C18, 5 mm, 4.6mm i.d. 15 cm,
Waters) was used at 40 C. The detection wavelength was set
to 285 nm. The injection volume was 20 ml.3. Results and discussion
3.1. Morphology of fenofibrate-loaded MPS and Pre MPS
Fig. 2 shows SEM images of PreMPS andMPS samples. PreMPS
(Fig. 2A) had a fiber-like structure with hundreds of micro-
meter in length and ca. 10 mm in width. Morphology of MPS
(Fig. 2B) was similar to that of Pre MPS, indicating that the
macroscopic structure of MPS was thermally stable and able
to maintain after calcination at 550 C. Magnified image
(Fig. 2C) revealed that several rod-like units with ca. 1 mm in
width aggregated and formed the fiber-like structure.Fig. 3 shows SEM images of fenofibrate-loaded samples. In
the SEM image of PM sample (Fig. 3A), both bulk fenofibrate
powder and fiber-like MPS structure were found. On the other
hand, fenofibrate-loaded samples prepared by solvent (Fig. 3B)
or melting (Fig. 3C and 3D) methods showed only fiber-like
structure. This demonstrated that fenofibrate molecules
interacted with Pre MPS/MPS during the drug loading process
and changed into different dispersion state comparing to that
in the physical mixture. It was considered that micro pores of
PreMPS/MPSwere important factor for this specific dispersion
state. Furthermore, the morphology of the sample with
percent of loaded fenofibrate up to 66% showed the particles
that could be considered as fenofibrate adsorbed onto outer
surfaces of MPS fiber-like structure (Fig. 3E and 3F).3.2. Physicochemical characterization of fenofibrate-
loaded MPS and Pre MPS
PXRD patterns and DSC curves of samples prepared by the
solvent method are shown in Fig. 4 and Fig. 5. In the PXRD
analysis, crystalline fenofibrate showed its characteristic
diffraction peaks. In contrast, the fenofibrate-loaded MPS at
20% and 33% gave halo patterns and diffraction peaks of
crystalline fenofibrate disappeared. This was confirmed by the
DSC analysis. DSC thermogram of crystalline fenofibrate
showed an endothermicmelting peak at 81 C. Melting peak of
fenofibrate was absent in these fenofibrate-loadedMPS. These
results suggested that fenofibrate was loaded into MPS with
dichloromethane as a vehicle and remained in an amorphous
state after removal of dichloromethane.
For Pre MPS where triblock copolymer Pluronic 123 still
remained in MPS pores, fenofibrate-loaded Pre MPS at 10%
Fig. 3 e SEM micrographs of fenofibrate-loaded MPS and Pre MPS prepared by solvent method and meting method; (A)
Physical mixture of MPS (FF: 33%), (B) Solv-MPS (FF: 33%), (C) Melt-Pre MPS (FF: 20%), (D) Melt-MPS (FF: 33%), (E) and (F) Melt-
MPS (FF: 66%).
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20% showed diffraction peaks of crystalline fenofibrate. This is
consistent with the DSC results that the melting peak of
fenofibrate was observed in drug-loaded Pre MPS at 20% and
33%. Since the Pre MPS pores were filled with triblock copol-
ymer Pluronic 123 and incorporating fenofibrates into MPS
poreswasmore difficult, it could be concluded that fenofibrate
molecules aggregated on outer surface of the Pre MPS and
crystallized as bulk fenofibrate.
PXRD patterns and DSC curves of samples prepared by the
melting method are shown in Fig. 6 and Fig. 7. Like the sam-
ples prepared by the solvent method, the PXRD patterns of
fenofibrate-loaded MPS at 20% and 33% exhibited halo pat-
terns and their DSC curves showed no endothermic peaks of
fenofibrate, indicating that fenofibrate loaded into MPS was in
an amorphous state. In the melting process, fenofibrate
should be in amolten state and be confined in the pore of MPS
as amorphous state. On the contrary, the MPS samples loadedup to 50% and 66% showed crystalline peaks of fenofibrate in
both PXRD and DSC results and their peak intensities became
stronger depending on a ratio of loaded fenofibrate. As shown
in SEM observation (Fig. 3E and 3F), it indicated that MPS pores
were saturated with fenofibrate and then excess fenofibrate
molecules adsorbed and crystallized onto the outer surface of
MPS.
The PXRD measurement of Pre MPS loaded at 10% gave
halo pattern. However crystalline peaks were observed in Pre
MPS loaded over 20%. This agreed with the result of samples
prepared by the solvent method. Crystallization of fenofibrate
could be due to prefilling of Pluronic 123 in micro pores of Pre
MPS.
The results obtained from PXRD and DSC experiments
demonstrated that by using the melting method which was
simple and solvent-free, fenofibrate molecules were loaded
into MPS as an amorphous state as same as sample prepared
by the solvent method. The drug loading capacity depended
Fig. 4 e PXRD patterns of fenofibrate-loaded MPS and Pre
MPS by solvent method; (a) Crystalline FF, (b) MPS, (c) Solv-
MPS (FF: 20%), (d) Solv-MPS (FF: 33%), (e) Pre MPS, (f) Solv-
Pre MPS (FF: 10%), (g) Solv-Pre MPS (FF: 20%), (h) Solv-Pre
MPS (FF: 33%).
Fig. 6 e PXRD patterns of fenofibrate-loaded MPS and Pre
MPS prepared by melting method; (a) Crystalline FF, (b)
MPS, (c) Melt-MPS (FF: 20%), (d) Melt-MPS (FF: 33%), (e) Melt-
MPS (FF: 50%), (f) Melt-MPS (FF: 66%), (g) Pre MPS, (h) Melt-
Pre MPS (FF: 10%), (i) Melt-Pre MPS (FF: 20%), (j) Melt-Pre
MPS (FF: 33%).
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loading fenofibrate molecules as an amorphous state was ca.
33%. It was proved that when overloading fenofibrate or
blocking micro pores with packed polymers like Pre MPS,
incorporating drug molecule into pores became physically
difficult and drug molecules aggregated on outer surface of
MPS resulting in crystallization at the outside.3.3. Dissolution test
Fig. 8 shows the dissolution profiles of samples prepared by
the solvent method. For fenofibrate-loaded MPS at 20% and
33%, fenofibrate was rapidly dissolved within the first 15 min.
The highly supersaturated concentration of fenofibrate was
achieved comparing to the dissolution of crystalline fenofi-
brate. As confirmed by PXRD and DSC measurement, drug
incorporated in the nanostructure of mesoporous silica wasFig. 5 e DSC thermograms of fenofibrate-loaded MPS and
Pre MPS prepared by solvent method; (a) MPS, (b) Solv-MPS
(FF: 20%), (c) Solv-MPS (FF: 33%), (d) Pre MPS, (e) Solv-Pre
MPS (FF: 10%), (f) Solv-Pre MPS (FF: 20%), (g) Solv-Pre MPS
(FF: 33%), (h) Crystalline FF.not in crystalline form but in amorphous form. The super-
saturated condition was facilitated by the drug molecules in
amorphous state.
For Pre MPS, drug-loaded Pre MPS at 10% showed the su-
persaturated condition within 15 min and remained constant
till 120 min. The increase in drug solubility and its supersat-
urated concentration could be explained by that drug in
amorphous state and Pluronic, a surfactant, were existed in
the drug-loaded Pre MPS sample. In drug-loaded Pre MPS at
20%, its supersaturated concentration was reached but
decreased rapidly. Moreover, no supersaturated condition
was observed in the drug-loaded Pre MPS at 33%. It suggested
that crystallization of drug at the outer surface of pore caused
the decrease in supersaturated condition and dissolution rate.
Fig. 9 shows the dissolution profiles of samples prepared by
the melting method. The dissolution profiles of fenofibrate-Fig. 7 e DSC thermograms of fenofibrate-loaded MPS and
Pre MPS bymeltingmethod; (a) MPS, (b) Melt-MPS (FF: 20%),
(c) Melt-MPS (FF: 33%), (d) Melt-MPS (FF: 50%), (e) Melt-MPS
(FF: 66%), (f) Pre MPS, (g) Melt-Pre MPS (FF: 20%), (h) Melt-Pre
MPS (FF: 33%), (i) Crystalline FF.
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prepared by the solvent method but the supersaturated con-
centration was higher. Samples with high percent drug
loading (50% and 66%) did not show any supersaturated con-
dition and drug crystallization in vessel was observed during
the dissolution test. It indicated that small amount of drug
may crystallize during the melting method, became nuclei
and accelerated the drug crystallization during the dissolution
test.
For Pre MPS, the supersaturated condition was achieved in
Pre MPS (FF: 10%) whereas the dissolved drug concentration
and dissolution rate decreased in samples with drug loading
at 20% and 33%. Although no crystallization out of solution
was observed during the dissolution test, results from PXRD
and DSC measurement showed that crystallization happened
during sample preparation by melting method. This may
affect their dissolution properties. For solvent and melting
methods, the most important factor affecting the solubiliza-
tion of fenofibrate was the quantity of drug loaded into the
nanopore of mesoporous silica.From the above results, drug in amorphous state could be
incorporated in the pore. The enhancement of solubility and
dissolution rate of fenofibrate, a poorly water-soluble drug,
was succeeded by using the nanosized pore of mesoporous
silica. Supersaturation of drug was obtained from samples
prepared by solvent and melting methods. Although drug
loading by the melting method tended to have a higher su-
persaturated concentration than that by the solvent method.4. Conclusion
The results from SEM, PXRD and DSC measurement showed
that fenofibrate in amorphous form could be incorporated into
mesoporous silica by both solvent and melting methods. The
drug-loaded quantity depended on the volume of pores.
Amorphous drug up to 33% could be loaded into the pore.
When drug was overloaded or pores were occupied by
macromolecule as in Pre MPS, the drug incorporation was
difficult and recrystallization occurred. For the dissolution test
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vent and melting methods could reach the supersaturated
condition. While the sample prepared from melting method
gave a higher supersaturated drug concentration. Themelting
method is a simple preparation process without using a sol-
vent. From this study, drug could be efficiently loaded into
MPS by melting method. It is easy to enhance the solubility
and dissolution rate of poorly water-soluble drug by loading
into mesoporous silica using the proposed melting method.r e f e r e n c e s
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